Form 4: Opko Health Sells Shares of GeneDx Holdings Corp.

Opko Health, a significant shareholder of GeneDx Holdings Corp., has sold a portion of its Class A common stock in two transactions.

Summary

• Opko Health, Inc., a 10% owner of GeneDx Holdings Corp., sold shares of Class A Common Stock on July 24, 2024, and July 26, 2024.
• On July 24, 2024, Opko Health sold 75,000 shares at a weighted average price of $33.7214 per share.
• On July 26, 2024, Opko Health sold 60,000 shares at a weighted average price of $33.8543 per share.
• Following these transactions, Opko Health directly owns 3,123,403 shares of GeneDx Holdings Corp.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing share sales, which is neutral in sentiment. It doesn't contain any information that would strongly suggest a positive or negative outlook for either company.

Industry Context

Sales of shares by significant shareholders are common and can be for a variety of reasons, including portfolio rebalancing or raising capital for other ventures. The impact on GeneDx's stock price will depend on market perception of the sale and the overall health of the company.

Comparison to Industry Standards

• It's common for major shareholders to periodically adjust their positions in publicly traded companies.
• Comparable transactions would include sales by large institutional holders in similar-sized biotech or healthcare companies.
• Without knowing Opko's specific reasons, it's difficult to assess whether this sale is unusual compared to industry norms.

Stakeholder Impact

• The share sale could potentially impact the stock price of GeneDx Holdings Corp., affecting shareholders.
• The impact on other stakeholders such as employees, customers, and suppliers is likely to be minimal unless the sale signals a larger strategic shift.

Key Dates